IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 256 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,846,940 | +296.6% | 625,701 | +513.6% | 0.01% | +400.0% |
Q2 2023 | $717,925 | +95.1% | 101,978 | +69.3% | 0.00% | +100.0% |
Q1 2023 | $368,011 | -55.9% | 60,231 | -53.9% | 0.00% | -50.0% |
Q4 2022 | $835,013 | +33.0% | 130,675 | +99.4% | 0.00% | +100.0% |
Q3 2022 | $628,000 | -52.8% | 65,538 | -45.6% | 0.00% | -50.0% |
Q2 2022 | $1,331,000 | +7294.4% | 120,522 | +11153.2% | 0.00% | – |
Q1 2022 | $18,000 | -97.1% | 1,071 | -96.7% | 0.00% | -100.0% |
Q4 2021 | $629,000 | -84.0% | 32,935 | -79.4% | 0.00% | -75.0% |
Q3 2021 | $3,939,000 | +787.2% | 159,744 | +1038.2% | 0.00% | +300.0% |
Q1 2021 | $444,000 | -70.8% | 14,035 | -69.6% | 0.00% | -80.0% |
Q3 2020 | $1,518,000 | +354.5% | 46,117 | +238.2% | 0.01% | +66.7% |
Q2 2019 | $334,000 | +145.6% | 13,634 | -11.5% | 0.00% | +200.0% |
Q4 2018 | $136,000 | +51.1% | 15,403 | +118.6% | 0.00% | 0.0% |
Q2 2018 | $90,000 | +8900.0% | 7,045 | +5674.6% | 0.00% | – |
Q3 2017 | $1,000 | -96.8% | 122 | -97.1% | 0.00% | – |
Q2 2017 | $31,000 | – | 4,202 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |